Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 9, 2013, Pages 2038-2047

  Ariën, Kevin K ^a   Venkatraj, Muthusamy ^b   Michiels, Johan ^a   Joossens, Jurgen ^b   Vereecken, Katleen ^a   Der Veken, Pieter Van ^b   Cuylaerts, Sal̈d ^a   Abdellati, Vicky ^a   Crucitti, Tania ^a   Heyndrickx, Leo ^a   Heeres, Jan ^b   Augustyns, Koen ^b   Lewi, Paul J ^b   Vanham, Guido ^a,b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cytotoxicity; Lactobacilli; Microbicides; NNRTIs; Triazines

Indexed keywords

DAPIVIRINE; MICROBICIDE;

ALGORITHM; ANTIVIRAL ACTIVITY; ARTICLE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MICROFLORA; SEXUAL TRANSMISSION; TOXICITY; VIRUS TRANSMISSION;

CYTOTOXICITY; LACTOBACILLI; MICROBICIDES; NNRTIS; TRIAZINES;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; CELL SURVIVAL; CELLS, CULTURED; CHEMOPREVENTION; DRUG EVALUATION, PRECLINICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TRIAZINES;

EID: 84882582456     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt166     Document Type: Article

References (45)

1. AriënKK, JespersV, VanhamG. HIVsexual transmissionandmicrobicides. Rev Med Virol 2011; 21: 110-33.
2. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464: 217-23.
3. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med 2012; 2: a006965.
4. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74. Erratum in: Science 2010; 333: 524.
5. Fernández-Romero JA, Thorn M, Turville SG et al. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007; 34: 9-14.
6. FletcherP, HarmanS, AzijnHet al. Inhibition ofhumanimmunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009; 53: 487-95.
7. Caron M, Besson G, Etenna SL et al. Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV. Virology 2010; 405: 225-33.
8. Kenney J, Aravantinou M, Singer R et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 2011; 6: e15835.
9. Cost M, Dezzutti CS, Clark MR et al. Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model. Antimicrob Agents Chemother 2012; 56: 3058-66.
10. van't Klooster G, Hoeben E, Borghys H et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010; 54: 2042-50.
11. Van Damme L, Szpir M. Current status of topical antiretroviral chemoprophylaxis. Curr Opin HIVAIDS 2012; 7: 520-5.
12. Singer R, Derby N, Rodriguez A et al. The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol 2011; 85: 5504-12.
13. Stolte-Leeb N, Loddo R, Antimisiaris S et al. Topical nonnucleoside reverse transcriptase inhibitor MC 1220 partially prevents vaginal RT-SHIV infection of macaques. AIDS Res Hum Retroviruses 2011; 27: 933-43.
14. Turville SG, Aravantinou M, Miller T et al. Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 2008; 3: e3162.
15. Kenney J, Singer R, DerbyNet al. Asingle dose of a MIV-150/zinc acetate gel provides 24h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24h after gel use. AIDS Res Hum Retroviruses 2012; 28: 1476-84.
16. Asahchop EL, Wainberg MA, Sloan RD et al. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother 2012; 56: 5000-8.
17. Selhorst P, Vazquez AC, Terrazas-Aranda K et al. Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrob Agents Chemother 2011; 55: 1403-13. Erratum in: Antimicrob Agents Chemother 2011; 55: 3645.
18. Mowbray CE, Burt C, Corbau R et al. Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. Bioorg Med Chem Lett 2009; 19: 5857-60.
19. Ludovici DW, Kavash RW, Kukla MJ et al. Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. Bioorg Med Chem Lett 2001; 11: 2229-34.
20. Mordant C, Schmitt B, Pasquier E et al. Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. Eur J Med Chem 2007; 42: 567-79.
21. AnastassopoulouCG, Marozsan AJ, MatetAet al. Escape of HIV-1 froma small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog 2007; 3: e79.
22. Gali Y, Ariën KK, Praet M et al. Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity. J Virol Methods 2010; 165: 186-97.
23. Kyongo JK, Jespers V, Goovaerts O et al. Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. PLoS One 2012; 7: e43951.
24. Singer R, Mawson P, Derby N et al. An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med 2012; 4: 150ra123.
25. Aravantinou M, Singer R, Derby N et al. The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT infection. AIDS Res Hum Retroviruses 2012; 28: 1467-75.
26. Fetherston SM, Geer L, Veazey RS et al. Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. J Antimicrob Chemother 2013; 68: 394-403.
27. Lewi P, Heeres J, Ariën K et al. Reverse transcriptase inhibitors as microbicides. Curr HIV Res 2012; 10: 27-35.
28. Van Herrewege Y, Michiels J, Van Roey J et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004; 48: 337-9.
29. Van Herrewege Y, Vanham G, Michiels J et al. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob Agents Chemother 2004; 48: 3684-9.
30. Terrazas-Aranda K, Van Herrewege Y, Lewi PJ et al. In vitro pre- and postexposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection. Antivir Chem Chemother 2007; 18: 141-51.
31. Schader SM, Colby-Germinario SP, Schachter JR et al. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. AIDS 2011; 25: 1585-94.
32. Fletcher PS, Elliott J, Grivel JC et al. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006; 20: 1237-45.
33. Di Fabio S, Van Roey J, Giannini G et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003; 17: 1597-604.
34. Nuttall JP, Thake DC, Lewis MG et al. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. Antimicrob Agents Chemother 2008; 52: 909-14.
35. Jespers VA, Van Roey JM, Beets GI et al. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIVpositive female volunteers. J Acquir Immune Defic Syndr 2007; 44: 154-8.
36. Nel AM, Coplan P, van de Wijgert JH et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009; 23: 1531-8.
37. Nel AM, Smythe SC, Habibi S et al. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010; 55: 161-9.
38. Nel AM, Coplan P, Smythe SC et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010; 26: 1181-90.
39. Lackman-Smith C, Osterling C, Luckenbaugh K et al. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother 2008; 52: 1768-81.
40. Ariën KK, Kyongo JK, Vanham G. Ex vivo models of HIV sexual transmission and microbicide development. Curr HIV Res 2012; 10: 73-8.
41. Doncel GF, Clark MR. Preclinical evaluation of anti-HIV microbicide products: new models and biomarkers. Antiviral Res 2010; 88 Suppl 1: S10-8.
42. Buckheit RW Jr, Buckheit KW. An algorithm for the preclinical development of anti-HIV topical microbicides. Curr HIV Res 2012; 10: 97-104.
43. Watson Buckheit K, Yang L, BuckheitRWJr. Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides. Antimicrob Agents Chemother 2011; 55: 5243-54.
44. Buckheit RW Jr, Hartman TL, Watson KM et al. The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors. Antivir Chem Chemother 2007; 18: 259-75.
45. Johnson TJ, Srinivasan P, Albright TH et al. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 2012; 56: 1291-9.